Impact of islet autoimmunity on the progressive β-cell functional decline in type 2 diabetes

Diabetes Care

Volumn 37, Issue 12, 2014, Pages 3286-3293

  Brooks Worrell, Barbara M ^a   Boyko, Edward J ^a   Palmer, Jerry P ^a  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C PEPTIDE; GLUCAGON; GLUTAMATE DECARBOXYLASE ANTIBODY; HLA ANTIGEN CLASS 2; INSULINOMA ASSOCIATED PROTEIN 2 ANTIBODY; UNCLASSIFIED DRUG; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 1; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE;

ADULT; ALLELE; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; CELL SPECIFICITY; CELLULAR IMMUNITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; ISLET AUTOIMMUNITY; LONGITUDINAL STUDY; MALE; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATHOGENESIS; PHENOTYPE; PILOT STUDY; PROSPECTIVE STUDY; T LYMPHOCYTE; CROSS-SECTIONAL STUDY; IMMUNOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AUTOANTIBODIES; AUTOIMMUNITY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLUTAMATE DECARBOXYLASE; HUMANS; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PILOT PROJECTS; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 8; T-LYMPHOCYTES;

EID: 84911865268     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-0961     Document Type: Article

References (38)

1. Ehses JA, Ellingsgaard H, Böni-Schnetzler M, Donath MY. Pancreatic islet in flammation in type 2 diabetes: from α and β cell compensation to dysfunction. Arch Physiol Biochem 2009;115:240-247
2. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 2008;31(Suppl. 2):S161-S164
3. Donath MY, Böni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic β-cell in type 2 diabetes. Physiology (Bethesda) 2009;24:325-331
4. Böni-Schnetzler M, Ehses JA, Faulenbach M, Donath MY. Insulitis in type 2 diabetes. Diabetes Obes Metab 2008;10(Suppl. 4):201-204
5. Butcher MJ, Hallinger D, Garcia E, et al. Association of proinflammatory cytokines and islet resident leucocytes with islet dysfunction in type 2 diabetes. Diabetologia 2014;57:491-501
6. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517-1526
7. Donath MY, Mandrup-Poulsen T. The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus. Nat Clin Pract Endocrinol Metab 2008;4:240-241
8. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009;32:1663-1668
9. Verge CF, Gianani R, Kawasaki E, et al. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun 1996;9:379-383
10. Naserke HE, Ziegler A-G, Lampasona V, Bonifacio E. Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes. J Immunol 1998;161:6963-6969
11. Kawasaki E, Yu L, Rewers MJ, Hutton JC, Eisenbarth GS. Definition of multiple ICA512/phogrin autoantibody epitopes and detection of intramolecular epitope spreading in relatives of patients with type 1 diabetes. Diabetes 1998;47:733-742
12. Palmer JP. Predicting IDDM: use of humoral immune markers. Diabetes Rev 1993;1:104-115
13. Groop LC, Bottazzo GF, Doniach D. Islet cell antibodies identify latent type I diabetes in patients aged 35-75 years at diagnosis. Diabetes 1986;35:237-241
14. Zimmet PZ, Tuomi T, Mackay IR, et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 1994;11:299-303
15. Juneja R, Hirsch IB, Naik RG, Brooks-Worrell BM, Greenbaum CJ, Palmer JP. Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes. Metabolism 2001;50:1008-1013
16. Gottsäter A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 1993;16:902-910
17. van Deutekom AW, Heine RJ, Simsek S. The islet autoantibody titres: their clinical relevance in latent autoimmune diabetes in adults (LADA) and the classification of diabetes mellitus. Diabet Med 2008;25:117-125
18. Davis TM, Wright AD, Mehta ZM, et al. Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 2005;48:695-702
19. Turner R, Stratton I, Horton V, et al.; UK Prospective Diabetes Study Group. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 1997;350:1288-1293
20. Bottazzo GF, Bosi E, Cull CA, et al. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia 2005;48:703-708
21. Seyfert-Margolis V, Gisler TD, Asare AL, et al. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes 2006;55:2588-2594
22. Herold KC, Brooks-Worrell B, Palmer J, et al.; Type 1 Diabetes TrialNet Research Group. Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes 2009;58:2588-2595
23. Brooks-Worrell BM, Starkebaum GA, Greenbaum C, Palmer JP. Peripheral blood mononuclear cells of insulin-dependent diabetic patients respond to multiple islet cell proteins. J Immunol 1996;157:5668-5674
24. Brooks-Worrell B, Gersuk VH, Greenbaum C, Palmer JPP. Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes. J Immunol 2001;166:5265-5270
25. Brooks-Worrell B, Warsen A, Palmer JP. Improved T cell assay for identification of type 1 diabetes patients. J Immunol Methods 2009;344:79-83
26. Brooks-Worrell BM, Greenbaum CJ, Palmer JP, Pihoker C. Autoimmunity to islet proteins in children diagnosed with new-onset diabetes. J Clin Endocrinol Metab 2004;89:2222-2227
27. Goel A, Chiu H, Felton J, Palmer JP, Brooks-Worrell B. T-cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe β-cell lesions in phenotypic type 2 diabetes. Diabetes 2007;56:2110-2115
28. Brooks-Worrell BM, Reichow JL, Goel A, Ismail H, Palmer JP. Identification of autoantibody-negative autoimmune type 2 diabetic patients. Diabetes Care 2011;34:168-173
29. Brooks-Worrell BM, Palmer JP. Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients. Clin Exp Immunol 2013;171:164-170
30. Brooks-Worrell BM, Juneja R, Minokadeh A, Greenbaum CJ, Palmer JP. Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients. Diabetes 1999;48:983-988
31. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care 2012;35(Suppl. 1):S11-S63
32. 3H recombinant human ligands. J Immunol Methods 1995;186:89-99
33. Bingley PJ, Williams AJ, Colman PG, et al.; T1DGC. Measurement of islet cell antibodies in the Type 1 Diabetes Genetics Consortium: efforts to harmonize procedures among the laboratories. Clin Trials 2010;7(Suppl.):S56-S64
34. Sosenko JM, Palmer JP, Rafkin-Mervis L, et al. Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008;31:2188-2192
35. Sarikonda G, Pettus J, Phatak S, et al. CD8 T cell reactivity to islet antigens is unique to type 1 while CD4 T cell reactivity exists in both type 1 and type 2 diabetes. J Autoimmun 2014;50:77-82.
36. Wang J, Miao D, Babu S, et al. Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity. J Clin Endocrinol Metab 2007;92:88-92
37. von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol 2007;7:988-994
38. Williams RC, Muller YL, Hanson RL, et al. HLA-DRB1 reduces the risk of type 2 diabetes mellitus by increased insulin secretion. Diabetologia 2011;54:1684-1692